Tests predictive of thrombosis in cancer

被引：25

作者：

Ay, Cihan ^{[1
]}

Pabinger, Ingrid ^{[1
]}

机构：

[1] Med Univ Vienna, Clin Div Haematol & Haemostaseol, Dept Med 1, A-1090 Vienna, Austria

来源：

THROMBOSIS RESEARCH | 2010年 / 125卷

关键词：

Venous thrombosis; Pulmonary embolism; Biomarkers; SOLUBLE P-SELECTIN; VON-WILLEBRAND-FACTOR; HIGH PLASMA-LEVELS; VENOUS THROMBOEMBOLISM; FACTOR-VIII; TISSUE FACTOR; RISK-FACTORS; D-DIMER; BLOOD-COAGULATION; VIENNA CANCER;

D O I：

10.1016/S0049-3848(10)70005-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is a close interrelation between cancer and haemostasis, which is characterized by changes in the haemostatic system, mostly an activation of coagulation in cancer patients. Venous thromboembolism (VTE) is a frequent complication of cancer and in particular of anticancer therapy and is associated with significant morbidity and mortality. As the occurrence of VTE in cancer patients is a life-threatening condition, clinical parameters or laboratory tests predictive of VTE might be helpful for early identification of patients at high or low risk of VTE in order to allow a tailored therapy assessment. Recently, some candidate laboratory parameters or biomarkers, such as blood count, P-selectin, D-Dimer, prothrombin fragment 1+2, clotting factor VIII and tissue factor, have been identified as predictors of the VTE risk in cancer. Interventional trials based on risk assessment with the use of biomarkers or risk scoring models are needed to demonstrate effectiveness and safety of tailored thromboprophylaxis. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：S12 / S15

页数：4

共 43 条

[11] The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study [J].

Dogan, M. ;

Demirkazik, A. ;

Konuk, N. ;

Yalcin, B. ;

Buyukcelik, A. ;

Utkan, G. ;

Tek, I. ;

Akbulut, H. ;

Sencan, O. ;

Icli, F. .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2006, 21 (04) :206-210

[12] ABNORMALITIES OF BLOOD-COAGULATION TESTS IN PATIENTS WITH CANCER [J].

EDWARDS, RL ;

RICKLES, FR ;

MORITZ, TE ;

HENDERSON, WG ;

ZACHARSKI, LR ;

FORMAN, WB ;

CORNELL, CJ ;

FORCIER, RJ ;

ODONNELL, JF ;

HEADLEY, E ;

KIM, SH ;

ODELL, R ;

TORNYOS, K ;

KWAAN, HC .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 88 (05) :596-602

[13] Thrombophilia in cancer [J].

Falanga, A .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (01) :104-110

[14] PROTHROMBIN FRAGMENT F1+2 PLASMA-CONCENTRATIONS IN PATIENTS WITH GYNECOLOGIC MALIGNANCIES [J].

HANZAL, E ;

TATRA, G .

GYNECOLOGIC ONCOLOGY, 1993, 49 (03) :373-376

[15] Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer [J].

Khorana, A. A. ;

Francis, C. W. ;

Menzies, K. E. ;

Wang, J. -G. ;

Hyrien, O. ;

Hathcock, J. ;

Mackman, N. ;

Taubman, M. B. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (11) :1983-1985

[16] Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study [J].

Khorana, AA ;

Francis, CW ;

Culakova, E ;

Lyman, GH .

CANCER, 2005, 104 (12) :2822-2829

[17] Development and validation of a predictive model for chemotherapy-associated thrombosis [J].

Khorana, Alok A. ;

Kuderer, Nicole M. ;

Culakova, Eva ;

Lyman, Gary H. ;

Francis, Charles W. .

BLOOD, 2008, 111 (10) :4902-4907

[18] Assessing Risk of Venous Thromboembolism in the Patient With Cancer [J].

Khorana, Alok A. ;

Connolly, Gregory C. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (29) :4839-4847

[19]

KIES MS, 1980, CANCER-AM CANCER SOC, V46, P831, DOI 10.1002/1097-0142(19800815)46:4<831::AID-CNCR2820460432>3.0.CO

[20]

2-L

← 1 2 3 4 5 →